Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Raised to $310.00

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its target price boosted by JPMorgan Chase & Co. from $300.00 to $310.00 in a research note published on Tuesday morning,Benzinga reports. They currently have an overweight rating on the specialty pharmaceutical company’s stock.

Several other analysts also recently commented on the stock. UBS Group raised their price objective on shares of Jazz Pharmaceuticals from $315.00 to $337.00 and gave the company a “buy” rating in a research report on Friday, September 11th. Royal Bank Of Canada boosted their price objective on Jazz Pharmaceuticals from $296.00 to $305.00 and gave the company an “outperform” rating in a research report on Tuesday. Robert W. Baird upped their price objective on Jazz Pharmaceuticals from $252.00 to $280.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 4th. Deutsche Bank Aktiengesellschaft increased their target price on Jazz Pharmaceuticals from $287.00 to $300.00 and gave the stock a “buy” rating in a research report on Wednesday, August 26th. Finally, Piper Sandler lifted their target price on Jazz Pharmaceuticals from $301.00 to $310.00 and gave the company an “overweight” rating in a research note on Tuesday, August 4th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $293.45.

Jazz Pharmaceuticals Trading Down 3.1%

Jazz Pharmaceuticals stock opened at $227.32 on Tuesday. Jazz Pharmaceuticals has a 12-month low of $128.80 and a 12-month high of $266.38. The firm has a market capitalization of $14.59 billion, a price-to-earnings ratio of 77.32, a P/E/G ratio of 0.47 and a beta of 0.38. The firm has a 50 day moving average of $229.71 and a 200 day moving average of $217.40. The company has a current ratio of 1.82, a quick ratio of 1.58 and a debt-to-equity ratio of 1.09.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share for the quarter, beating the consensus estimate of ($4.03) by $0.15. The business had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $1.21 billion. Jazz Pharmaceuticals had a net margin of 4.37% and a return on equity of 16.88%. The company’s revenue for the quarter was up 10.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $8.13 earnings per share. As a group, research analysts predict that Jazz Pharmaceuticals will post 10.84 earnings per share for the current year.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 6,000 shares of the firm’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $215.84, for a total transaction of $1,295,040.00. Following the completion of the transaction, the director owned 339,875 shares in the company, valued at $73,358,620. This trade represents a 1.73% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Renee D. Gala sold 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 3rd. The stock was sold at an average price of $225.37, for a total value of $225,370.00. Following the sale, the chief executive officer directly owned 140,394 shares in the company, valued at $31,640,595.78. This trade represents a 0.71% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 101,121 shares of company stock worth $24,858,332 in the last quarter. 4.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Several institutional investors have recently bought and sold shares of the business. USA Financial Formulas purchased a new position in Jazz Pharmaceuticals during the first quarter worth $25,000. Pension & Wealth Management Advisors Inc. bought a new stake in shares of Jazz Pharmaceuticals in the 3rd quarter worth about $32,000. Ameritas Advisory Services LLC bought a new stake in shares of Jazz Pharmaceuticals in the 2nd quarter worth about $47,000. Thurston Springer Miller Herd & Titak Inc. bought a new stake in shares of Jazz Pharmaceuticals in the 2nd quarter worth about $61,000. Finally, Elevation Wealth Partners LLC boosted its stake in shares of Jazz Pharmaceuticals by 156.4% during the 3rd quarter. Elevation Wealth Partners LLC now owns 259 shares of the specialty pharmaceutical company’s stock worth $60,000 after purchasing an additional 158 shares during the period. Institutional investors own 89.14% of the company’s stock.

Key Stories Impacting Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz beat Q3 2026 estimates, reporting revenue of $1.24 billion versus expectations of $1.21 billion, with revenue up 10.4% year over year. The company also raised its 2026 revenue outlook to approximately $4.78 billion–$4.85 billion, according to the earnings coverage. Q3 earnings call summary
• Positive Sentiment: Several firms, including RBC, Barclays, Morgan Stanley and JPMorgan, issued bullish commentary or raised price targets after the results, signaling continued analyst confidence. Barclays price target coverage
• Neutral Sentiment: CEO Renée Galá sold 1,000 shares and director Bruce Cozadd sold 6,000 shares. Both transactions were made under pre-arranged Rule 10b5-1 plans; Galá retained 140,394 shares and Cozadd retained 339,875. Planned sales are less informative about executives’ current views than discretionary transactions. CEO sale filing

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.